VA-CTA
13.6.2019 17:05:12 CEST | Business Wire | Press release
CES Asia 2019 concluded today, shining a spotlight on the transformative technologies that will revolutionize the Asian marketplace and improve lives around the world. With its largest exhibit floor to date – an over 14% increase from 2018 – CES Asia 2019 cemented itself as Asia’s most influential tech event and the place to experience this rapid pace of innovation hitting the Asian market.
“At CES Asia 2019 we saw a convergence of industries,” said Gary Shapiro, president and CEO, CTA. “From global tech leaders to fashion, travel and tourism visionaries, it’s clear that tech innovation for the Asian marketplace is accelerating at a lightning speed and spurring new partnerships and growth on a global scale.”
A curated show that is now in its fifth year, CES Asia 2019 featured more than 550 exhibiting companies across the entire tech ecosystem, Including 115 startups from seven countries. Japan, Korea and the U.S. more than doubled their exhibitor presence year-over-year at CES Asia 2019. There was also a strong representation of over 24 Swiss companies at the show.
“CES Asia 2019 has been very successful for Nu Skin Enterprises. This is our first effort to present our automated controlled environment agriculture technology to the world,” said Brent Petersen, marketing and communications, Nu Skin Enterprises. “Asia is a very important market for Nu Skin, so based on the tremendous success and interest in our products during the show we’ve decided to double our exhibition space for CES Asia 2020.”
The CES Asia Conference Program featured three full days of sessions with more than 150 executives from global brands including APTIV, IBM China, Mobvoi, Deloitte, WeRide and SAP. Sessions covered a wide range of topics, including smart mobility, machine learning, digital health, blockchain and sustainability. View the full conference schedule here.
“BoCo is changing the future,” said Dr. Zhou Xinhong, CEO, BoCo. “CES Asia provided us the platform to showcase our mission – to use advanced bone conduction technology to build a better relationship between people and sound.”
CES Asia Keynotes (click here to see a recap of day one keynotes )
Industry visionaries took to the CES Asia keynote stage to discuss the future of innovation and trends that will redefine the industry. Dr. Chang Huang, co-founder and VP of Horizon Robotics, unveiled Horizon Robotics’ advancements in edge computing and the company’s strategy for future AI applications. Dr. Huang introduced joint optimization and flexible features of the Horizon algorithm, chip and compiler.
During his keynote address on June 12, Mr. Nobu Ide, president and CEO of Wacom, unveiled the company’s vision for the future of digital ink. Ide showcased innovative solutions in Extended Reality (XR) to enable XR drawing in open and 3D environments. He also highlighted the importance of partnerships to empower designers with creative freedom including several they had with Gravity Sketch, Magic Leap, Staedtler, BIC, Leapie and iFLYTEK.
Michelle Toh, multiplatform editor at CNN, moderated a keynote panel focused on Tech Innovation in Travel and Tourism. Wong Hong, president of Greater China and Singapore at Delta Air Lines, stressed the responsibility to envision future technology revolutions in order to keep up with customers’ growing needs. Helen Huang, president of Greater China at MSC Cruises, discussed how IoT and AI enable broad connectivity and personalization opportunities, allowing companies to optimize services and customer experiences.
CES Asia Conference Sessions
Yesterday’s Tech4Good panel addressed the ability of technology to solve global challenges. The panel was presented by Citypreneurs, a UN-backed platform for impact-driven innovation, and explored sustainable ventures and frontier technologies aimed to achieve sustainability through partnerships at the city level.
The Power of Diversity, Innovation and Sustainability panel, presented by Ladies Who Tech, showcased China’s emerging role as an innovation hub. The panel featured experts and visionaries who explored the power that the convergence of diversity, innovation and sustainability, has to make the world a better place.
CES Asia Exhibitor Announcements
Exhibitors unveiled products and announced partnerships during 22 media events throughout the show (click here to view day one announcements ). Major product announcements from exhibitor news conferences included:
- HiScene – Introduced AR smart glasses HiAR G200
- Ningbo Sogen Electronics Technology Co., Ltd. – Launched its latest BH03 bone conduction Bluetooth headphones with a wraparound titanium design to make them lighter and more comfortable to wear, giving consumers an extraordinary experience.
CES Asia Award Programs
CES Asia featured several awards programs honoring cutting-edge products and technologies. The Best of CES Asia Awards, presented by ZOL, recognized breakthrough innovation across product categories, including AI, vehicle tech and startups, with Hisense taking home the top prize with its 4K Laser Television 100L7. Click here to see the full list of winners .
CES Asia 2019 was strong across all measures with a preliminary analysis indicating more than 40,000 attendees, including more than 1,400 members of the global media. CES Asia is one of Asia’s fastest growing tech events, bringing together the entire tech ecosystem to build brands, forge partnerships and celebrate the best in consumer tech in Asia. For the latest news, photos, b-roll and more, visit CESAsia.com . CES Asia will return to Shanghai, June 10-12, 2020.
About CES Asia:
Owned and produced by the International CES (Shanghai) Exhibition Co. Ltd. and co-produced by Shanghai Intex Exhibition Co., Ltd (Shanghai Intex), CES Asia is the premier event for the consumer technology industry, showcasing the full breadth and depth of the innovation value-chain in the Asian marketplace. Key global businesses come to this event to grow and reinforce their brand by showcasing the latest products and technologies to consumer tech industry executives, foreign buyers and international media. Attendees have exclusive access to some of the largest brands from China and around the world, while celebrating the innovation that defines the consumer technology sector.
About International CES (Shanghai) Exhibition Co. Ltd. and CTA:
International CES (Shanghai) Exhibition Co. Ltd. is a wholly foreign-owned enterprise by the Consumer Technology Association (CTA), a trade association representing the $398 billion U.S. consumer technology industry, which supports more than 18 million U.S. jobs. More than 2,200 companies – 80 percent are small businesses and startups; others are among the world’s best-known brands – enjoy the benefits of CTA membership including policy advocacy, market research, technical education, industry promotion, standards development and the fostering of business and strategic relationships. CTA also owns and produces CES® – the world’s gathering place for all who thrive on the business of consumer technologies. Profits from CES are reinvested into CTA’s industry services.
About Shanghai Intex:
Taken independent in July 2016, Shanghai Intex Exhibition (Co., Ltd.) was originally founded in 1995 as the pioneering exhibition organizing business of Intex Shanghai, the first joint venture venue management business in Shanghai. Shanghai Intex is jointly overseen by the China Council for the Promotion of International Trade (CCPIT) Shanghai and PNO Exhibitions, giving it the perfect combination of domestic and international resources. Over the last 20 years, Shanghai Intex has organized more than 100 tradeshows and over 1000 conferences, with a sum total show space in excess of 2 million square meters. Shanghai Intex runs a number of internationally renowned exhibitions covering the music industry, healthcare, lifestyle, advanced manufacturing, public transportation, floriculture, consumer electronics, technology and more.
UPCOMING EVENTS
-
CEO
Summit
June 23-26 – Prague, Czech Republic -
Technology
& Standards Fall Forum
September 23 – Los Angeles, CA -
CES
Unveiled in Paris
October 22 – Paris, France -
CES
Unveiled in Amsterdam
October – Amsterdam, Netherlands -
CES
2020
January 7-10, 2020 – Las Vegas, NV
View source version on businesswire.com: https://www.businesswire.com/news/home/20190613005502/en/
Contact:
Teresa Hsu 703-907-5259 thsu@CTA.tech
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
